# Medicinal Cannabis Prescription Before Psychiatric Admission: Audit Results > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medicinal-cannabis-psychiatric-inpatient-use-audit/ > **Published:** 2026-03-27T19:24:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:36:28-04:00 > **Clinical Summary:** This audit examines medicinal cannabis psychiatric inpatient use, revealing prescription patterns and safety considerations in psychiatric admissions. --- CED Clinical Relevance  #62Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic PsychiatryInpatientObservationalSafetyAustralia Journal Journal of psychiatric practice Study Type Observational Study Population Human participants Why This Matters This is the first systematic examination of medicinal [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns among psychiatric inpatients, providing crucial real-world data on a vulnerable population where evidence remains limited. Understanding prescription patterns and associated outcomes in this cohort is essential for informing clinical decision-making and safety protocols. Clinical Summary This retrospective audit of 752 psychiatric inpatients in Brisbane found 4.7% had received medicinal cannabis prescriptions within 90 days prior to admission. The study examined demographics, indications, formulations, and clinical presentations associated with these prescriptions. While the prevalence appears relatively low, the study provides important baseline data on medicinal [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns in psychiatric populations where controlled evidence remains sparse and clinical outcomes are poorly characterized. Dr. Caplan’s Take “This audit fills a critical knowledge gap by documenting real-world medicinal cannabis use in psychiatric patients, though the 4.7% prevalence suggests either conservative prescribing or potential underreporting. The lack of outcome data limits our ability to draw clinical conclusions about efficacy or safety in this vulnerable population.” Clinical Perspective 🧠 Clinicians should recognize that a small but meaningful proportion of psychiatric inpatients may be using medicinal cannabis, necessitating careful medication reconciliation and monitoring for potential interactions or exacerbation of symptoms. This data supports the need for more rigorous prospective studies examining both benefits and risks of medicinal cannabis in psychiatric populations before widespread adoption. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Medicinal%20Cannabis%20Prescription%20Before%20an%20Inpatient%20Psychiatric%20Admission%3A%20A%20Ret...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41894185/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41894185/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Medicinal%20Cannabis%20Prescription%20Before%20an%20Inpatient%20Psychiatric%20Admission%3A%20A%20Ret...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41894185/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41894185/](https://pubmed.ncbi.nlm.nih.gov/41894185/) Table of Contents - [FAQ](#FAQ)[How common is medicinal cannabis use among psychiatric inpatients?](#How_common_is_medicinal_cannabis_use_among_psychiatric_inpatients) - [Should clinicians be concerned about medicinal cannabis contributing to psychiatric hospitalizations?](#Should_clinicians_be_concerned_about_medicinal_cannabis_contributing_to_psychiatric_hospitalizations) - [What psychiatric conditions are most commonly associated with medicinal cannabis prescriptions?](#What_psychiatric_conditions_are_most_commonly_associated_with_medicinal_cannabis_prescriptions) - [How should clinicians manage patients using medicinal cannabis during psychiatric admissions?](#How_should_clinicians_manage_patients_using_medicinal_cannabis_during_psychiatric_admissions) - [Does medicinal cannabis affect length of stay in psychiatric units?](#Does_medicinal_cannabis_affect_length_of_stay_in_psychiatric_units) - [Related](#Related) ## FAQ #### How common is medicinal cannabis use among psychiatric inpatients? This Australian study found that 4.7% of psychiatric inpatients (35 out of 752 patients) had been prescribed medicinal cannabis within 90 days before their hospital admission. This suggests medicinal cannabis use is relatively uncommon but present in the acute psychiatric inpatient population. #### Should clinicians be concerned about medicinal cannabis contributing to psychiatric hospitalizations? While this study demonstrates an association between recent medicinal cannabis prescriptions and psychiatric admissions, it cannot establish causation due to its observational design. Clinicians should carefully assess each patient’s cannabis use history and consider potential interactions with psychiatric conditions, but medicinal cannabis may not directly cause hospitalization. #### What psychiatric conditions are most commonly associated with medicinal cannabis prescriptions? The study does not specify which psychiatric diagnoses were most common among medicinal cannabis users in their sample. However, the research highlights the need for more evidence regarding medicinal [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) and efficacy in psychiatric populations, as current evidence is limited. #### How should clinicians manage patients using medicinal cannabis during psychiatric admissions? Clinicians should obtain detailed medication histories including medicinal cannabis formulations, dosing, and timing of last use. Consider potential withdrawal effects, drug interactions with psychiatric medications, and whether continuation or discontinuation is appropriate based on individual clinical circumstances. #### Does medicinal cannabis affect length of stay in psychiatric units? While the study collected data on length of stay for patients with recent medicinal cannabis prescriptions, the specific impact on hospitalization duration is not detailed in the available summary. Further analysis would be needed to determine if medicinal cannabis use influences recovery time or discharge planning. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Medicinal Cannabis Prescription Before an Inpatient Psychiatric Admission: A Retrospective Observational Audit.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41894185/”, “about”: “journal psychiatric practice observational study medicinal”, “isPartOf”: “Journal of psychiatric practice”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Oliver's Law: Campaign Calls for Changes to Medical Cannabis Prescribing in Psychiatric Conditions](https://cedclinic.com/psychiatric-cannabis-prescribing-guidelines-olivers-law/) Explore advocacy efforts aimed at reforming [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) prescribing practices for psychiatric patients to improve safety and efficacy. [Learn More](https://cedclinic.com/psychiatric-cannabis-prescribing-guidelines-olivers-law/) [Will Medicinal Cannabis Help My Mental Health? Evidence and Risks](https://cedclinic.com/medicinal-cannabis-demand-mental-health-soars-evidence-risks/) An educational overview of the current evidence and potential risks of medicinal cannabis use in [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) treatment. [Read Article](https://cedclinic.com/medicinal-cannabis-demand-mental-health-soars-evidence-risks/) [Medicinal Cannabis Has Gone Mainstream, But Australia's Struggling to Cope](https://cedclinic.com/cannabinoid-clinical-research-excellence-australia/) Insight into the challenges faced by Australia's healthcare system in managing the rise of medicinal cannabis use. [Discover More](https://cedclinic.com/cannabinoid-clinical-research-excellence-australia/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).